Ensign Peak Advisors, Inc Uni Qure N.V. Transaction History

Ensign Peak Advisors, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	BUY	$26.01 - $38.22 $358,938 - $527,436	13,800 New	13,800 $435,000
Q1 2021 May 12, 2021	SELL	$29.24 - $42.03 $31,579 - $45,392	-1,080 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$35.98 - $47.66 $58,467 - $77,447	-1,625 Reduced 60.07%	1,080 $40,000
Q1 2020 May 11, 2020	SELL	$40.01 - $73.97 $115,868 - $214,217	-2,896 Reduced 51.71%	2,705 $128,000
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $207,965 - $417,946	5,601 New	5,601 $402,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.